Opdivo, Bristol-Myers Squibb
Nivolumab Indicated as Neoadjuvant NSCLC Treatment
The FDA approved nivolumab (Opdivo, Bristol Myers Squibb) in combination with platinum-doublet chemotherapy to ...
APRIL 12, 2022
FDA Approves Opdivo as Third-Line Rx for SCLC
The FDA granted accelerated approval to nivolumab (Opdivo, Bristol-Myers Squibb) for the treatment of patients with ...
AUGUST 21, 2018
Load more